Therapeutic approaches of magnetic nanoparticles for the central nervous system

Dilnawaz, Fahima; Sahoo, Sanjeeb K.

doi:10.1016/j.drudis.2015.06.008

Cited by 61 publications

(34 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Iron is the most popular core material due to its low toxicity and easy elimination through the endogenous iron metabolic pathway and is usually used in oxide form because it is a more stable state [87]. Multiple coating is used to enhance drug delivery, such as polysaccharides (dextrin), polyethylene-glycol (PEG), phospholipids, peptides, for protection of the metal core from the body, improve pharmacokinetics, lower toxicity [107]. Fluorophores/radionuclides are used for basic research and for diagnostic purposes [108].…”

Section: Nanocarriers Nanoparticles and Vectorsmentioning

confidence: 99%

Overcoming the Blood–Brain Barrier. Challenges and Tricks for CNS Drug Delivery

2019

View full text Add to dashboard Cite

Treatment of certain central nervous system disorders, including different types of cerebral malignancies, is limited by traditional oral or systemic administrations of therapeutic drugs due to possible serious side effects and/or lack of the brain penetration and, therefore, the efficacy of the drugs is diminished. During the last decade, several new technologies were developed to overcome barrier properties of cerebral capillaries. This review gives a short overview of the structural elements and anatomical features of the blood–brain barrier. The various in vitro (static and dynamic), in vivo (microdialysis), and in situ (brain perfusion) blood–brain barrier models are also presented. The drug formulations and administration options to deliver molecules effectively to the central nervous system (CNS) are presented. Nanocarriers, nanoparticles (lipid, polymeric, magnetic, gold, and carbon based nanoparticles, dendrimers, etc.), viral and peptid vectors and shuttles, sonoporation and microbubbles are briefly shown. The modulation of receptors and efflux transporters in the cell membrane can also be an effective approach to enhance brain exposure to therapeutic compounds. Intranasal administration is a noninvasive delivery route to bypass the blood–brain barrier, while direct brain administration is an invasive mode to target the brain region with therapeutic drug concentrations locally. Nowadays, both technological and mechanistic tools are available to assist in overcoming the blood–brain barrier. With these techniques more effective and even safer drugs can be developed for the treatment of devastating brain disorders.

show abstract

Section: Nanocarriers Nanoparticles and Vectorsmentioning

confidence: 99%

Overcoming the Blood–Brain Barrier. Challenges and Tricks for CNS Drug Delivery

2019

View full text Add to dashboard Cite

show abstract

“…A variety of materials have been utilized for nanoparticle delivery to the brain, including dendrimers, polymers, micelles, hydrogels, liposomes and solid lipids, gold, silica, silver‐based inorganics, iron or iron oxides, quantum dots, and carbon‐based particles . For each of these nanoparticle systems, important physicochemical characteristics that affect drug delivery and efficacy include size, surface charge, composition, molecular weight (MW), material structure, elasticity, shape, and material porosity (Table ).…”

Section: Nanoparticle Physicochemical Properties For Overcoming Physimentioning

confidence: 99%

Systems‐level thinking for nanoparticle‐mediated therapeutic delivery to neurological diseases

Curtis

Zhang

Liao

et al. 2016

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Neurological diseases account for 13% of the global burden of disease. As a result, treating these diseases costs $750 billion a year. Nanotechnology, which consists of small (~1-100 nm) but highly tailorable platforms, can provide significant opportunities for improving therapeutic delivery to the brain. Nanoparticles can increase drug solubility, overcome the blood-brain and brain penetration barriers, and provide timed release of a drug at a site of interest. Many researchers have successfully used nanotechnology to overcome individual barriers to therapeutic delivery to the brain, yet no platform has translated into a standard of care for any neurological disease. The challenge in translating nanotechnology platforms into clinical use for patients with neurological disease necessitates a new approach to: (1) collect information from the fields associated with understanding and treating brain diseases and (2) apply that information using scalable technologies in a clinically-relevant way. This approach requires systems-level thinking to integrate an understanding of biological barriers to therapeutic intervention in the brain with the engineering of nanoparticle material properties to overcome those barriers. To demonstrate how a systems perspective can tackle the challenge of treating neurological diseases using nanotechnology, this review will first present physiological barriers to drug delivery in the brain and common neurological disease hallmarks that influence these barriers. We will then analyze the design of nanotechnology platforms in preclinical in vivo efficacy studies for treatment of neurological disease, and map concepts for the interaction of nanoparticle physicochemical properties and pathophysiological hallmarks in the brain. WIREs Nanomed Nanobiotechnol 2017, 9:e1422. doi: 10.1002/wnan.1422 For further resources related to this article, please visit the WIREs website.

show abstract

“…In medicine, drug delivery with nanoparticles (NPs) is one of most dynamically evolving research areas. 5 However, fundamental understanding of issues related to toxicity and environmental impact of nanoscale materials is still under investigation. 6 During the past several years, there have been numerous toxicological investigations of airborne NPs and their impact on occupational health and the environment.…”

Section: Introductionmentioning

confidence: 99%

Assessing the axonal translocation of CeO2 and SiO2 nanoparticles in the sciatic nerve fibers of the frog: an ex vivo electrophysiological study

Kastrinaki

Samsouris

Kosmidis

et al. 2015

IJN

View full text Add to dashboard Cite

The axonal translocation of two commonly used nanoparticles in medicine, namely CeO 2 and SiO 2 , is investigated. The study was conducted on frog sciatic nerve fibers in an ex vivo preparation. Nanoparticles were applied at the proximal end of the excised nerve. A nerve stimulation protocol was followed for over 35 hours. Nerve vitality curve comparison between control and exposed nerves showed that CeO 2 has no neurotoxic effect at the concentrations tested. After exposure, specimens were fixed and then screen scanned every 1 mm along their length for nanoparticle presence by means of Fourier transform infrared microscopy. We demonstrated that both nanoparticles translocate within the nerve by formation of narrow bands in the Fourier transform infrared spectrum. For the CeO 2 , we also demonstrated that the translocation depends on both axonal integrity and electrical activity. The speed of translocation for the two species was estimated in the range of 0.45–0.58 mm/h, close to slow axonal transportation rate. Transmission electron microscopy provided direct evidence for the presence of SiO 2 in the treated nerves.

show abstract

Therapeutic approaches of magnetic nanoparticles for the central nervous system

Cited by 61 publications

References 63 publications

Overcoming the Blood–Brain Barrier. Challenges and Tricks for CNS Drug Delivery

Overcoming the Blood–Brain Barrier. Challenges and Tricks for CNS Drug Delivery

Systems‐level thinking for nanoparticle‐mediated therapeutic delivery to neurological diseases

Assessing the axonal translocation of CeO2 and SiO2 nanoparticles in the sciatic nerve fibers of the frog: an ex vivo electrophysiological study

Contact Info

Product

Resources

About